Albert Labs International Corp (CSE:ABRT) said it has filed a patent application for its proprietary manufacturing process developed at its Vancouver facility which facilitates the production and scaling of highly potent yields of its psilocybin-based KRN-101 active pharmaceutical ingredient.
The company said its bioreactor technology is efficient, economical, and sustainable, ensuring pharmaceutical quality and consistent production of its natural, tryptamine-based medicines.
The international Patent Cooperation Treaty patent application covering its manufacturing process was filed with the United States Patent and Trademark Office, Albert Labs said.
READ: Albert Labs appoints Dr Sara Tai as principal investigator for its upcoming trial on KRN-101
The technology is being used by the company to produce its primary drug target, psilocybin-based KRN-101, which Albert Labs said would treat cancer patients suffering from mental distress.
It will also support the company’s growth plans as it pursues a clinical expansion strategy with various global regulatory authorities.
Albert Labs research and development lead Dr Jean Saayman said that this technology was a very innovative approach to solving the scale-up issues faced by processes utilizing high-value shear-sensitive organisms.
“The novel bioreactor and processing methods result in better yields with lower post-processing requirements, and the advantages for commercial API production are exciting,” Dr Saayman said in a statement.
Albert Labs CEO Dr Michael Raymont added that having the capability to produce natural medicines at scale and to the pharmaceutical quality provided the company with an invaluable asset.
“This milestone demonstrates the company's in-house biochemical engineering expertise and simultaneously establishes Albert Labs as a market leader in the controlled production and scaling of pharmaceutical quality, natural tryptamine-based medicines,” he said.
Albert Labs is a pharmaceutical drug development company, focused on gaining regulatory approval for active compounds in the treatment of mental health, and providing rapid access to effective prescription medicines for people suffering from mental health disorders.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie